Anti-HLA-E Purified

*Nachmani D, Zimmermann A, Oiknine Djian E, Weisblum Y, Livneh Y, Khanh Le VT, Galun E, Horejsi V, Isakov O, Shomron N, Wolf DG, Hengel H, Mandelboim O: MicroRNA editing facilitates immune elimination of HCMV infected cells. PLoS Pathog. 2014 Feb 27;10 (2) :e1003963., URL: https://pubmed.ncbi.nlm.nih.gov/24586166/, *Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P: Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia. 2011 Sep;13 (9) :822-30., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=tremante+e+cerboni+c , *Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP.: HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol. 2005 Jan;66 (1) :1-12., URL: https://www.ncbi.nlm.nih.gov/pubmed/15620456?dopt=, *Sibilio L. et al., Tissue Antigens 62, 339, 2003. (Abstract 45 from the 3rd Int. Conference on HLA-G, Paris, July 2003) ., URL:

The antibody MEM-E/07 recognizes an extracellular epitope on native surface-expressed HLA-E, but not denaturated heavy chain of HLA-E. HLA-E belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on many types of the human cells. The published results revealed that the antibody cross-reacts with some classical MHC Class I molecules (MHC Class Ia) : HLA-B7 (strongly), HLA-B8 (moderately), HLA-B27, -B44 (weakly) .